In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
The last time we checked in on Ratio Therapeutics co-founders Dr Jack Hoppin and Dr John Babich, they were working out of a WeWork co-working space in downtown Boston, just beginning their
Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.